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Abstract
Introduction: Iceland is well suited for epidemiological research due to well-kept patient records, easy followup
of patients and nation-wide health care databases. This study provides a nationwide 30-year epidemiological
overview of the HIV epidemic in the country.
Materials and methods: Retrospective study on all HIV positive individuals in Iceland, 1983-2012. Clinical data,
CD4+ T-cell counts, plasma HIV RNA, proportion of late presenters and effectiveness of combined antiretroviral
therapy (cART) were compared by different time intervals.
Results: In total, 313 were diagnosed with HIV in 1983-2012, thereof 222 (71%) men and 91 (29%) women. Most
infections (65%) were acquired outside the country. Mean incidence of HIV was 3.7/100,000 inhabitants/year, with a
significant increase in 2010-2012 (p=0.0113), related to misuse of the prescription drug methylphenidate among
intravenous drug users. Official prescriptions for this drug increased from 3.5 in 2002 to 17.4 defined daily doses/
1,000 inhabitants/day in 2012. Mortality decreased by 70% during the study period (p=0.0275). Proportion of late
presenters decreased from 74% in the first decade to 36% during the third (p=0.0001). After 6 months of ART, CD4+
T-cells increased by only 26 cells/µl on average during the monotherapy era (1987-1995; p=0,174), by 107 cells/µl
during the early-cART era (1996-2004; p<0.0001) and by 159 cells/µl during the late-cART era (2005-2012;
p<0,0001). Similarly, progressively greater reductions in plasma HIV RNA were observed from 1996-2004 to
2005-2012 (p<0.0001).
Conclusions: HIV incidence remained relatively low in Iceland until 2010, when it increased significantly due to
spread among IDUs. The majority of HIV infections diagnosed in Iceland were imported. With ever more effective
drug treatments on CD4+ T-cells and plasma HIV RNA, the number of AIDS diagnoses and deaths has decreased
dramatically.
Keywords: HIV; Iceland; Epidemiology; Injection drug users; Men
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Introduction
The first cases of the acquired immunodeficiency syndrome, or
AIDS, were described in 1981 in the US [1,2]. HIV was isolated in
1983 [3] and the first HIV positive blood samples in Iceland are from
the same year [4]. As of 2012, over 70 million people have become
infected, of which over 35 millions have died due to AIDS [5]. Sub-
Saharan Africa has been the most severely affected geographical area,
containing 69% of the people living with HIV worldwide. In Europe, it
is estimated that more than 1.5 million people are infected and more
than 1.1 million in the US [6]. Epidemiological studies suggest that
despite advances in diagnosis and treatment, HIV incidence has been
on the rise in Eastern-Europe in the past few years [5], whereas the
incidence has dropped by over 30% in the US from 2002 to 2011 [7].
Antiretroviral drugs have been the basis of HIV treatment since the
first nucleoside reverse transcriptase inhibitor was introduced in 1987
[8], followed by other antiretrovirals, and in 1996 by combined
Antiretroviral Therapy (cART) [9]. Furthermore, new methods to
monitor plasma HIV RNA as well as drug resistance tests on viruses
have greatly facilitated treatment-related decisions [10,11]. At the
present time newly infected HIV-positive individuals who enjoy good
health care can have a comparable life expectancy to those in the same
age group in the general population [12,13]. However, HIV infected
individuals are still at risk of getting opportunistic infections and other
complications [14], especially Late Presenters (LP) or those who
receive inadequate therapy [15,16].
Migrants with HIV are a growing population in many Western
European countries, especially those with an HIV infection acquired
through heterosexual transmission originated from sub-Saharan
Africa, Asia and the Caribbean [17-19]. In 2011, over half of all new
HIV diagnoses were among migrants in Sweden, Norway, Finland and
the UK.
Men who have Sex with Men (MSM) have been one of the most
important risk groups for HIV infection since the early 1980s.
Epidemics of HIV among MSM have resurfaced in many countries
despite improved treatment, education and prevention strategies
[5,20-22]. Health authorities have made it a priority to target this and
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other key populations in an effort to slow the spread of the global
epidemic [22].
Iceland is ideally suited for epidemiological studies, with good
record keeping and government-based health care. Only a few studies
exist on HIV in Iceland, one of which was an overview of the first 10
years of the epidemic [23]. At that time the incidence of AIDS in the
country was 1.36 per 100.000/year, with a mean survival of only 22
months following the diagnosis. MSM were the most common risk
group while infections in IDU were only sporadic. Subsequently, the
proportion of HIV diagnoses among migrants has increased, with
corresponding changes in viral serotypes [19,24].
All permanent residents of Iceland have access to government-
funded health care and medical care to HIV positive patients has been
provided free of charge from the onset of the epidemic. The aims of
this study were to give a nationwide overview of HIV during the first
30 years in Iceland, 1983-2012. The incidence of HIV and AIDS,
clinical characteristics and risk groups were described and compared.
Furthermore, CD4+ T-cell counts and plasma HIV RNA were analysed
in the context of ART (antiretroviral therapy) from the beginning of
the epidemic in this unselected nationwide cohort.
Methods
Setting, diagnosis and recording of HIV
Iceland had 235,537 inhabitants in the beginning of 1983 and
321,857 at the end of 2012 [25]. All diagnoses of HIV in Iceland are
performed in a central virology laboratory using ELISA and Western
blot for confirmation according to standard CDC protocols and
definitions; the disease is reportable to the Director of Health in
Iceland. HIV patients who reside in Iceland get their clinical care from
the Department of infectious diseases at Landspitali University
Hospital. A comprehensive list of HIV patients was generated by
searching the clinical and virology databases at the University Hospital
and cross-referencing with data at the Directorate of Health for the
period 1983-2012. Data on methylphenidate use in the country was
obtained from The Icelandic Medicines Agency. The study was
approved by the Landspitali Bioethics committee (ref 45/2012) and
registered at the Data Protection Agency of Iceland (ref
2012111366HGK/--).
Review of clinical data
Medical records of all HIV positive individuals who had been
diagnosed, treated and/or monitored at the National University
Hospital of Iceland were reviewed. The information included age at
diagnosis, gender, country of origin, risk group, origin of infection,
time of diagnosis, AIDS-defining condition, ART (medications and
dates of treatment), laboratory results (plasma HIV RNA and CD4+ T-
cell count) and outcomes. Vital status of patients was checked using
the national registry of citizens (Registers Iceland). The definition of
AIDS used in this study was based on European guidelines, which
require an AIDS-defining condition to be diagnosed for that
individual to be diagnosed with AIDS [26]. Persons presenting with
CD4+ T-cell counts <350 cells/µl or an AIDS-defining condition at the
time of HIV diagnosis are called late presenters (LP) [27]. For
epidemiologic analysis the study period was divided into three 10-year
intervals (decades I,II and III).
Effectiveness of ART
Effectiveness of ART in this unselected cohort was compared using
plasma HIV RNA and CD4+ T-cell count in ART naive HIV patients
before and after approximately 6 months of treatment as an endpoint.
To compare treatment effects, three time periods were compared;
monotherapy era (1987-1995); early cART era (1996-2004); and late
cART era (2005-2012). Data of plasma HIV RNA were only available
from 1996.
Statistical analysis
To calculate incidence and mortality, population figures from
Statistics Iceland (Hagstofa Islands) [25] were used. For statistical
comparisons the unpaired and paired t-tests as well as the chi-square
test were used as appropriate, with a two tailed p-value of <0.05.
Results
Epidemiology
Overall, 313 individuals were diagnosed with HIV in Iceland
between January 1, 1983 and December 31, 2012, of which 222 (71%)
were male and 91 (29%) were female. At the end of 2012 62 had died,
of which 39 (14% of HIV positive individuals who stayed at least 12
months in the country) died due to AIDS. During the observation
period 75 individuals left permanently or moved from the country, 41
of whom had stayed in the country for less than 12 months after HIV
diagnosis. At the end of 2012, 176 individuals were receiving active
care, thereof 34% women and 66% men.
Gender I: 1983 -
1992
II: 1993 -
2002
III: 2003 - 2012 Total
Number of men 76 (88%) 61 (69%) 85 (61%) 222
(71%)
Number of
women
10 (12%) 27 (31%) 54 (39%) 91 (29%)
Total 86 (27%) 88 (28%) 139 (44%) 313
Table 1: Distribution of new HIV diagnoses by gender in three 10-year
time periods.
The mean age at diagnosis was 34.9 years (range: 2-78 years). The
largest age group was 26-35 years, comprising 40% of all diagnosed
with HIV. An overview of basic epidemiologic parameters by study
decades is shown in Table 1. There was a marked increase in the
number of new diagnoses in the third decade of the study compared to
the first one (p=0.0004). Numbers of new HIV diagnoses in women
increased both relatively and absolutely, from 10 (12%) in the first
decade to 54 (39%) in the third (p<0.0001). The annual incidence of
HIV infection, expressed as number of new diagnosed infections per
100,000 inhabitants is shown in Figure 1A. During the entire period it
was 3.7 on average, 2.1 in women and 5.3 in men. During the study
period 69 patients were diagnosed with AIDS (22% of all HIV positive
individuals), 16 women (18% of all women) and 53 men (24% of all
men); 20 were foreign born (17% of all foreign-born HIV positive
persons). The mean age at diagnosis was 40 years (range: 18–77 years).
The annual incidence of AIDS is shown in Figure 1B; and the annual
mortality from AIDS is shown in Figure 1C. During the study 62
deaths were recorded of which 39 listed AIDS as the cause of death or
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57% of all patients receiving an AIDS diagnosis in the country. The
other 24 individuals died of various other causes, such as heart diseases
and cancers not believed to be related to HIV. The mean age at death
due to AIDS was 42.3 years (range: 22-79 years.) The incidence of
death from AIDS was 0.47 per 100,000 inhabitants per year. A
significant decrease in mortality from AIDS was noted, from 0.71 in
the first half of the study to 0.22 in the second half (p=0.0275). Only 5
women died from AIDS (31% of all women diagnosed with AIDS) and
35 men (66% of all men diagnosed with AIDS).
Figure 1: A) HIV incidence, B) AIDS incidence and C) mortality
due to AIDS from 1983 to 2012 (per 100.000 inhabitants) in
Iceland.
Origins and risk groups
The associations between risk groups, country of birth (native vs
foreign-born) and probable country of infection (Iceland vs other
countries) in the patient cohort is shown in Table 2. As shown, 192
(61%) of the HIV positive population were born in Iceland while 121
(39%) were foreign-born. A minority of the women (44%) were born
in Iceland while 68% of the men were native Icelanders. Of the 248
individuals where information was available regarding probable
country of infection, 35% became infected in Iceland and 65%
elsewhere. Of the 86 who likely became infected in Iceland only 7 were
foreign-born (8%). Almost half of all Icelanders with a documented
origin of infection became infected outside the country (43%) whereas
the vast majority (94%) of foreign-born individuals contracted HIV
abroad.
Origin of infection
Risk group Country of
origin
Iceland Other Unknown Total
Men
MSM Iceland 24 23 36 83
Other 2 12 4 18
IDU Iceland 22 2 4 28
Other 1 9 2 12
Heterosexual
intercourse
Iceland 7 18 3 28
Other 2 8 1 11
Other* Iceland 0 6 7 13
Other 0 26 3 29
Total, men  58 104 60 222
Women
IDU Iceland 13 1 0 14
Other 1 1 0 2
Heterosexual
intercourse
Iceland 10 9 1 20
Other 1 36 1 38
Other* Iceland 3 1 2 6
Other 0 10 1 11
Total, women  28 58 5 91
Total, men and women 86 162 65 313
Table 2: Number of new HIV diagnoses by sex, risk groups, country of
origin and origin of infection. MSM=Men who have Sex with Men.
IDU: Injection Drug Users. *Other risk groups: Infection by blood
products; from mother to child or unknown.
Information was available regarding probable mode of infection in
260 individuals, most commonly male homosexual (39%) and
heterosexual intercourse (37%). A majority (74%) of infections in IDU
took place domestically while 43% of MSM and 22% of those infected
by heterosexual intercourse contracted the virus within Iceland.
The temporal associations between HIV diagnoses in Iceland by
risk groups and country of birth are shown in Figure 2. As shown,
close to 80% of HIV positive individuals diagnosed before the year
2000 were born in Iceland but subsequently the proportion of foreign-
born persons has increased steadily, mostly in persons infected by
heterosexual intercourse.
Citation: Indridason H, Gudmundsson S, Karlsdottir B, Löve A, Briem H, et al. (2014) Long Term Nationwide Analysis of HIV and AIDS in
Iceland, 1983-2012. J AIDS Clin Res 5: 387. doi:10.4172/2155-6113.1000387
Page 3 of 7
J AIDS Clin Res
ISSN:2155-6113 JAR, an open access journals Volume 5 • Issue 12 • 1000387
Five infections by blood products were documented, of which 3
reportedly took place in Iceland (retrospectively diagnosed in blood
samples in 1985, 1986, 1989) and two elsewhere (reported in 1990 and
2011 in Iceland).
Figure 2: HIV diagnoses in Iceland by risk groups per year (n=313)
where a) shows diagnoses in people born in Iceland and b) outside
of Iceland. Other risk groups: Infection by blood products, from
mother to child or unknown (n=53). c) Methylphenidate use in
Iceland, presented as defined daily doses per 1,000 inhabitants per
year.
Outbreak in IDU population
At the end of 2012, 21.5% of all HIV positive individuals who have
received care in Iceland reportedly contracted the virus by IDU, most
of which were related to an outbreak which probably started in 2007,
followed by a dramatic increase in 2009-2012 (Figure 2). From 2007,
38 HIV infections in this group were diagnosed. Six of those
individuals have died (causes unrelated to HIV) and one has moved
from the country, leaving 31 of them in active care. Of the HIV
positive IDU since 2007, the median CD4+ T-cell count at diagnosis
was 600 cells/µl. Seven of them (18%) were late presenters and two had
no known CD4+ T-cell count near the time of diagnosis. The most
commonly used or preferred IV drug in this group was
methylphenidate, used by at least 87% before the time of diagnosis.
Figure 2C shows the increase in prescribed methylphenidate use in
Iceland in defined daily doses (DDD) per 1,000 inhabitants per day. It
increased from 3.5 in 2002 to 17.4 DDD/1,000 inhabitants/day in 2012.
In total, 23 of this group were receiving cART as of July 2014 (74% of
IDU in active care). The median most recent CD4+ T-cell count of
those IDU who have been receiving cART was 544 cells/µl, from a
median of 467 cells/µl at the time of diagnosis (p=0.1364). In the same
group, 19 (83%) had plasma HIV RNA levels of less than 50/ml in
their most recent measurement.
CD4+ T-cell counts at diagnosis and late presenters
Fairly comprehensive data regarding CD4+ T-cell counts at the time
of diagnosis was available for the last two decades of the study,
1993-2012. An increase was noted from a median cell count of 355 in
the second decade to 499 in the third. At least 104 patients (53% of
those with a documented CD4+ T-cell count within 6 months from
diagnosis) were LP (with <350 CD4+ T-cells/µl and/or AIDS). Only
12% of LP presented with AIDS. The proportion of LP, of those with a
documented CD4+ T-cell count, decreased from 74% in the first
decade to 65% in the second and 36% in the last (p=0.0001). The
proportion of LP among IDU was 23%, among heterosexuals 55% and
among MSM 51%. Foreign-born LP were 36 (35%) in total.
Effectiveness of cART
At the end of 2012, 82% of active patients were receiving cART in
Iceland. Of those who had received cART for 6 months or more 91%
had undetectable levels of plasma HIV RNA. The effect of antiviral
therapy on plasma HIV RNA and CD4+ T-cell count by the three
study periods is summarized in Table 3. The increase in CD4+ T-cell
count was not significant during the monotherapy era, but following
the early adoption of cART a significant increase was noted, with even
furher improvements during the most recent period (late cART-era).
Similar results were observed with respect to plasma HIV RNA
measurements. An average decrease of 2.19 log (p<0.0001) was noted
after 6 months of treatment during the early cART era while the
decrease was 3.20 log (p<0.0001) during the late cART era.
Undetectable HIV RNA, defined as less than 50 copies/ml was
observed among 57% of patients reveiving antiviral therapy during the
early cART era, while this goal was subsequently achieved among 85%.
Discussion
This study encompasses all known cases of HIV in Iceland in 30
years, providing a detailed analysis of changes during an unusually
long observation period in an unselected nationwide cohort. We
demonstrate that HIV incidence remained relatively low and stable in
Iceland from the beginning of the epidemic until 2010-2012 when an
outbreak occurred among IDU. In this respect it contrasts with the
trends in most other western countries where HIV incidence has
generally been stable or decreasing [5]. In the United States the annual
incidence of HIV has been relatively stable or slightly decreasing but it
has been considerably higher than in Iceland, close to 20/100,000 for
most of the 2000s [7,20,28,29]. Historically, the Nordic countries have
had a low incidence of HIV compared to most other countries in
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Europe. Over the past decade the annual incidence of HIV has ranged
from 4-6/100.000 inhabitants in Norway, Denmark and Sweden
[30-32]. On average, the incidence has been lowest in Iceland and
Finland among the Nordic countries [33] while in Greenland it has
been highest, although it has seen a slow decline in recent years [34].
A big proportion of new HIV patients in the Nordic countries are
foreign-born. In Sweden this was the case for at least 71% of all people
reported with a new HIV infection in 2010 and 2011 [32]. Most of
them were infected heterosexually prior to arriving in Sweden but the
MSM population still accounts for the largest proportion of new cases
domestically. Data from Denmark for 2012 shows that about 50% of
new HIV diagnoses were among tourists and immigrants, while over
half became infected outside of Denmark for the first time in over 10
years [31]. In Finland, over half of new HIV patients in 2011, for the
first time, were foreign-born and overall HIV incidence per 100,000
increased slightly from 2000, being 2.8 in 2000 compared to 3.6 in
2010 [33]. In Norway, most HIV patients infected sexually are
immigrants and while new HIV cases in MSM declined a bit year-
over-year in Norway in 2012, they increased again in 2013 [30]. Thus,
foreign-born HIV patients are increasingly becoming a bigger part of
the HIV epidemic in the Nordic countries but the domestic MSM
population remains very important. In fact, even after many years of
research and prevention efforts, high prevalence and incidence of HIV
has been reported in MSM around the world [35]. In many high-
income countries, such as Australia, the UK, France, and the USA,
overall HIV incidence trends are declining except in MSM, in what has
been described as re-emergent epidemics. In large parts of Africa, Asia,
and Latin America, the highest rates of HIV infection in any risk
group are in these men. Due to the resilient nature of the epidemic in
MSM and other key populations globally, including IDU, the World
Health Organization recently released new guidelines on HIV
prevention, diagnosis, treatment and care to try to combat the
epidemic more effectively [22].
  CD4+ T-cell count Plasma HIV RNA
Time period Number
of ART
naïve
who
received
ARTa
Mean
before
first ART,
cells/µl
Mean
change
after
6month
ART,
cells/µl
Mean
before
first ART,
log
Mean
change
after 6
month ART,
log
Monotherapy
era
(1987-1995)
47 266
(192;339)
26 (-28;81) N/Ab N/Ab
Early cART
era
(1996-2004)
66 275
(223;326)
107
(71;143)*
4,35
(4,12;4,59)
-2,19
(-2,51;1,87)*
Late cART
era
(2005-2012)
78 295
(223;367)
159
(129;189)*
4,67
(4,46;4,87)
-3,20
(-3,46;-2,93)*
Total 191
Table 3: The effect of ART on ART-naïve individual’s plasma HIV
RNA and CD4+ T-cell count. 95% confidence interval in parentheses.
*Significant change (p<0.0001).
aHIV positive individuals who received ART for 6 months or more
who have not received ART previously for more than 5 months.
bPlasma HIV RNA measurements not done before 1996.
Many similarities can be seen between the results of this long-term
nationwide study and global trends in HIV in other affluent societies,
including the increasing proportion of women and imported cases
[17]. It should be noted however that many of the foreign-born
individuals had already been diagnosed and sometimes treated
elsewhere before moving to Iceland. In the last years of the study
period MSM still remain one of the most important risk groups in the
country, surpassed in numbers only by IDU due to the outbreak of
2009-2012. Recent data show, however that the spread in IDU has
subsided while the number of new infections in MSM remains
relatively high and may even be increasing [4]. Although drug users
may pose a challenge to the health care system due to medical non-
compliance and no-shows in the clinics, our data suggest that most of
them may be started on ART with good treatment results if they
receive regular reminders and positive reinforcement, even in the
setting of continued drug use. Since 2010, early initiation of cART has
been recommended to most HIV infected IDU, irrespective of CD4+
T-cell count, to reduce risk of further spread (treatment as
prevention). The outbreak among the IDU in Iceland has since
subsided, which is not unexpected, since outbreaks in this population
tend to be relatively short lived [36]. Other Nordic nations
experienced similar outbreaks many years earlier, such as Finland in
1998 [37] while Denmark, Norway and Sweden all experienced similar
outbreaks around the mid 1980s where HIV incidence in IDU fell as
sharply as it rose after about 2-4 years [36]. Interestingly, while many
of the HIV positive IDU in Iceland used multiple IV drugs, the most
popular one was the psychostimulant prescription drug
methylphenidate, but heroin and amphetamine were the most
common ones in Denmark, Norway and Sweden [36]. Most IDU who
use methylphenidate inject themselves frequently due to the short half-
life [38,39], thus increasing the risk of sharing needles. Additionally,
IV methylphenidate use has been associated with worse pulmonary
morbidity and mortality compared to IV heroin and cocaine use [39].
The results of this study underline the benefits of increasingly
effective cART. Moreover, comparisons on CD4+ T-cell counts at the
time of diagnosis suggests that patients in Iceland are generally being
diagnosed earlier and thus interventions to reduce spread can be made
earlier. Consequently, the number of new AIDS cases and deaths due
to AIDS have decreased dramatically.
The proportion of HIV-infected individuals who present late, and
thus have higher morbidity, mortality risk and infectivity compared to
others [40-42], has remained high over the past decade in Western
Europe [43]. LP represent as much as 50% of all HIV patients in many
Western-European countries [43-47], a proportion that could likely be
lowered with more effective testing and earlier entry into care [48,49].
In particular, we feel that more targeted education and screening
among MSM in Iceland would be warranted, given the high
proportion of LP in this group. Late presentation of HIV infection is
not just a problem of the past. The results of this study show that the
proportion of LP of all new HIV diagnoses has decreased significantly
and is much lower in recent years than in Sweden for example, where
about 60% of new HIV diagnoses in 2011 were LP, the majority of
which were heterosexual immigrants [32]. The part of the HIV
positive population that remains unaware of their infection is very
important since close to half of all new HIV transmission events are
believed to be originated from that group [41,50]. It is also important
to note that universal screening has been advocated in settings where
the seroprevalence of HIV infection exceeds 0.1% [51], which is not
the case in Iceland.
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This study has some limitations due to its retrospective nature,
mostly due to lack of information, especially from the early years of
the epidemic. Additionally, the number of undiagnosed HIV positive
individuals in Iceland has not been estimated, but this might add 20%
to the known HIV positive population [41,50].
In summary, the annual incidence of HIV infection remained
relatively low in Iceland from the early days of the epidemic until 2010,
when it increased significantly due to an outbreak among IDU related
to methylphenidate use, which has now subsided. Most IDU can be
treated effectively with ART. Our study shows that MSM remain the
most important risk group for HIV infection within the domestic
population, suggesting that more educational and preventive efforts
are needed. The proportion of late presenters has steadily decreased. In
addition, with ever more effective drug treatments on CD4+ T-cells
and plasma HIV RNA, the number of AIDS diagnoses and deaths has
decreased dramatically.
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